Akeso, Inc. (HKG:9926)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
107.30
+5.30 (5.20%)
At close: Mar 6, 2026
46.09%
Market Cap 98.84B
Revenue (ttm) 2.75B
Net Income (ttm) -927.04M
Shares Out 921.14M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE 240.43
Dividend n/a
Ex-Dividend Date n/a
Volume 8,170,625
Average Volume 5,520,124
Open 100.50
Previous Close 102.00
Day's Range 99.60 - 107.80
52-Week Range 60.60 - 179.00
Beta 0.28
RSI 51.39
Earnings Date Mar 16, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 3,529
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9926
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.